Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Perrigo Company    PRGO

PERRIGO COMPANY (PRGO)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 4 897 M
EBIT 2017 983 M
Net income 2017 233 M
Debt 2017 2 694 M
Yield 2017 0,74%
Sales 2018 5 018 M
EBIT 2018 1 039 M
Net income 2018 494 M
Debt 2018 2 098 M
Yield 2018 0,76%
P/E ratio 2017 52,52
P/E ratio 2018 21,98
EV / Sales2017 3,05x
EV / Sales2018 2,86x
Capitalization 12 267 M
More Financials
Company
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products.It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences.The CHC segment includes... 
Sector
Pharmaceuticals
Calendar
02/27Earnings Release
More about the company
Surperformance© ratings of Perrigo Company
Trading Rating : Investor Rating :
More Ratings
Latest news on PERRIGO COMPANY
02/21PERRIGO : Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%
AQ
02/20PERRIGO CO PLC : Change in Directors or Principal Officers (form 8-K)
AQ
02/20PERRIGO : Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
PR
02/20PERRIGO : Appoints Ronald L. Winowiecki as Chief Financial Officer
PR
02/19PERRIGO : Announces Quarterly Dividend
AQ
02/15PERRIGO : To Release Fourth Quarter And Calendar Year 2017 Financial Results On ..
AQ
02/15PERRIGO : Announces Quarterly Dividend
PR
02/08PERRIGO : To Release Fourth Quarter And Calendar Year 2017 Financial Results On ..
PR
02/01PERRIGO : Announces Final FDA Approval Of A Generic Version Of Estrace® Cream
AQ
02/01PERRIGO : Announces Tentative FDA Approval for the Generic Version of Soolantra ..
AQ
More news
Sector news : Pharmaceuticals - NEC
01:46pPUMA BIOTECHNOLOGY : EU panel recommends against nod for Puma Biotech's breast c..
RE
12:30pSANOFI : Says U.S. Waiting Period for Bioverativ Has Expired
DJ
11:10aSHIRE : FDA to Conduct Priority Review of Shire Genetic-Disorder Drug
DJ
08:48aNOVARTIS : Greek Parliament Approves Bribery and Price Fix Inquiry on Novartis -..
DJ
02/22NOVARTIS : Greek Parliament Investigates Politicians in Novartis Bribery Probe
DJ
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 90,3 $
Spread / Average Target 3,7%
EPS Revisions
Managers
NameTitle
Uwe Röhrhoff President & Chief Executive Officer
Mary Lauren Brlas Chairman
Ronald Janish Executive VP-Global Operations and Supply Chain
Ron L. Winowiecki Chief Financial Officer
Thomas Farrington Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
PERRIGO COMPANY12 267
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.27%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.06%148 618